Wegovy ratings: what the evidence says and what patients report

What do the clinical trial ratings for Wegovy actually tell us?

The headline figure for Wegovy comes from STEP 1: a phase-3 randomised controlled trial in which around 1,960 adults with obesity or overweight plus at least one weight-related condition were assigned to semaglutide 2.4mg or a placebo, alongside a reduced-calorie diet and increased activity. At 68 weeks, the semaglutide group lost an average of about 15% of body weight against roughly 2.4% in the placebo group. That's a substantial and statistically significant gap, and it's the figure most clinicians and regulators point to when assessing how well this medicine performs.

Trial ratings, though, represent averages. Some participants in STEP 1 lost considerably more; others, less. The trial population was selected carefully, participants had to meet specific BMI and health criteria, commit to lifestyle support, and remain engaged throughout. Real-world outcomes can differ from trial figures in both directions. Adherence to the dosing schedule, how far someone can titrate up (the full semaglutide dosing pathway moves from 0.25mg to a maintenance dose over several months), and whether a person sustains lifestyle changes all influence where they land. The trial data sets a reasonable benchmark; it isn't a personal forecast.

NICE reviewed this evidence thoroughly before issuing its recommendation for Wegovy in 2023. The NICE technology appraisal TA875 concluded semaglutide was clinically effective and recommended it for adults meeting specific BMI and comorbidity thresholds within specialist services. That recommendation is itself a form of institutional rating, one that carries considerable weight.

How does the 7.2mg dose change the ratings picture?

Since STEP 1, Novo Nordisk has developed a higher maintenance dose. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2mg Wegovy pen (one injection per week) for adults with a BMI of 30 or above. Trial data for this strength reported an average weight loss of around 20.7% over 72 weeks, narrowing the gap that previously separated Wegovy from tirzepatide (Mounjaro) at its highest dose.

This matters for how people interpret Wegovy ratings they read online. Reviews written before early 2026 reflect experience with the 2.4mg maintenance dose only. The 7.2mg pen is newer, and its real-world profile is still accumulating. If you're reading forum posts or aggregated scores, it's worth checking when they were written and which dose the reviewer was on. A rating on 1.0mg, mid-titration, says something quite different from one at full maintenance. Our overview of things to know before starting Wegovy covers what the dose escalation phase typically feels like, which shapes early impressions considerably.

It's also worth noting that the 7.2mg pen is licensed only for BMI 30 or above, the cardiovascular-risk and other indications that semaglutide holds don't extend to this dose presentation. A prescriber will confirm which dose pathway is appropriate at assessment.

What do people consistently flag as affecting their rating of Wegovy?

Patient experience data and clinical reporting consistently point to a few factors that shape how people rate the medicine. First, nausea. It is the side effect most commonly mentioned during the titration phase, particularly after moving from one dose to the next. For most people it settles within a few weeks, but those who review early in treatment tend to rate it lower for this reason alone. Understanding that nausea is largely a phase, not a permanent feature, changes how you read those reviews.

Second, appetite suppression. People who find it striking tend to rate the medicine highly for precisely the reason others find unsettling: food simply becomes less interesting. The experience of cravings on Wegovy is something our prescribers discuss regularly, because it surprises people in both directions.

Third, injection experience. If you're wondering whether the Wegovy injection stings, many people report minimal discomfort, particularly once technique is established. It's a factor in early ratings that tends to drop off as a concern over time.

On the cost side, private treatment pricing is one of the most common reasons people hesitate. Our page on Wegovy costs in the UK addresses what honest pricing looks like, and why a single transparent price including prescription and clinical review is the benchmark to compare against, not just the headline number. If you're actively budgeting for treatment, our Wegovy savings page sets out the options worth knowing about before you commit. It's an honest acknowledgement that this kind of treatment is an investment, and most people searching for ratings are quietly doing the maths on whether it's worth it.

Is a good clinical rating the same as a good fit for you?

Wegovy's ratings in trials and regulatory assessments are strong. A NICE recommendation and a solid evidence base from peer-reviewed trials aren't given easily. But a medicine's general effectiveness rating and its suitability for a particular person are two different things. Contraindications, other medicines being taken, personal health history and the specific weight-related conditions someone has all feed into whether Wegovy is the right choice, or whether another licensed treatment would serve better.

The NHS patient information on semaglutide sets out the known side effects and safety profile clearly, and it's worth reading before treatment. At nume (sorry, at our pharmacy) every consultation is read by a GPhC-registered Independent Prescriber, not processed by software. They look at the whole picture before any treatment is approved, which is ultimately more useful than any aggregated rating.

If you have further questions, our frequently asked questions cover a lot of the practical detail, or you can get in touch directly.